EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The evolving treatment landscape for CSCC

David M Miller

Archives of Dermatological Research · 2025

DOI: 10.1007/s00403-025-03933-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von David M Miller. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, USA. dmiller4@mgh.harvard.edu. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Skin Neoplasms, Carcinoma, Squamous Cell, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape for cutaneous squamous cell carcinoma (CSCC) is evolving, with immunotherapy transforming care across all stages of disease and expanding the role of dermatologists. While surgery and radiotherapy remain cornerstones for localized CSCC, immune checkpoint inhibitors (ICIs) offer durable responses and survival benefits in advanced cases. Emerging approaches, including neoadjuvant, adjuvant, and intralesional ICIs, provide dermatologists with opportunities to integrate these therapies into practice, potentially enhancing surgical outcomes and preserving function in high-risk, resectable CSCC. Preliminary data on anti-PD-1 therapy as a preventive strategy for actinic neoplasia syndrome introduces new avenues for long-term management, though further evidence is needed. As systemic immunotherapy becomes increasingly relevant in dermatology, addressing immunotherapy-related adverse events requires interdisciplinary collaboration and specialized training. These advancements emphasize the expanding responsibilities of dermatologists in CSCC management while highlighting the importance of continued research and thoughtful application of these therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsSkin NeoplasmsCarcinoma, Squamous CellImmunotherapyHumansNeoadjuvant TherapyDermatologyCombined Modality Therapy

Stichwörter der Autor:innen

Cutaneous squamous cell carcinomaImmune checkpoint inhibitorImmunotherapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, USA. dmiller4@mgh.harvard.edu.
  • Department of Dermatology, Massachusetts General Hospital, 15 Parkman St. Room 132, Boston, MA, 02114, USA. dmiller4@mgh.harvard.edu.
  • Harvard Medical School, Boston, MA, USA. dmiller4@mgh.harvard.edu.

Zitieren

APA

Miller, D. M. (2025). The evolving treatment landscape for CSCC. Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-03933-5

Vancouver

Miller DM. The evolving treatment landscape for CSCC. Archives of Dermatological Research. 2025. doi:10.1007/s00403-025-03933-5

BibTeX
@article{Miller2025,
  author = {Miller, David M},
  title = {The evolving treatment landscape for CSCC},
  journal = {Archives of Dermatological Research},
  year = {2025},
  doi = {10.1007/s00403-025-03933-5}
}
Kostenlos starten →